RxDoctor Payments Data

Bridget Beier, DO

Endocrinology, Diabetes & Metabolism · Bethel Park, PANPI 1538376736

Payments from drug & device makers

$2,832in general payments, 2019–2025

Across 53 payments — averaging $53.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Amgen$255
  • Novo Nordisk$159
  • Abbott$145
  • Boston Scientific$99
  • Radius Health, Inc.$93
  • plus $357 from 12 others

What the payments were for

  • Speaking & faculty fees$1,37549%
  • Food & beverage$1,34848%
  • Education$1094%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,832 in reported general payments places this provider in the 60th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$105,019
Medicare patients
321
Services billed
3,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide669$936,357
MounjaroTirzepatide430$544,301
JardianceEmpagliflozin351$395,172
Tresiba Flextouch U-200Insulin Degludec149$166,471
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog115$89,236
TradjentaLinagliptin80$80,054
Humalog Kwikpen U-200Insulin Lispro22$65,306
RybelsusSemaglutide21$44,134
Tresiba Flextouch U-100Insulin Degludec77$42,578
Fiasp FlextouchInsulin Aspart (Niacinamide)32$41,313
Humalog Kwikpen U-100Insulin Lispro124$39,924
TrulicityDulaglutide24$38,568
Nano 2nd Gen Pen NeedlePen Needle, Diabetic282$35,753
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$34,958
Novolog FlexpenInsulin Aspart125$34,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$159$991,183731 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$36$591,434472 claims
AbbVieSynthroid$31$18,971313 claims
Sanofi-aventis U.S. LLCLantus$41$1,95711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

Other endocrinology, diabetes & metabolism in Bethel Park

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →